Quince Therapeutics, Inc.
QNCX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662774
No open-market purchases or sales by Quince Therapeutics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $4.74M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Quince Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Quince Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Senner Christopher J. | Director | – | Jun 15, 2026 | 2 |
| Lamond David | Director | 2,347,545Indirect | Jun 15, 2026 | 2 |
| Roberts Brigette | Chief Corp. Affairs Officer | – | Jun 11, 2026 | 1 |
| Ryan Charles S. | President | 130,009 | Jan 23, 2026 | 1 |
| Thye Dirk | CEO and CMO | 739,885Indirect | Jan 23, 2026 | 2 |
| Hannah Brendan | CBO, COO & CCO | 361,827 | Jan 23, 2026 | 2 |
| McLoughlin Margaret | Director | 8,000 | Jan 21, 2026 | 1 |
| Bray June | Director | – | Jan 21, 2026 | 1 |
| Benatti Luca | Director | 39,179 | Dec 29, 2025 | 2 |
| Ryan Una S | Director | – | Jun 6, 2025 | 0 |
| Patni Rajiv | Director | – | Jun 6, 2025 | 0 |
| Janhofer Guenter | Chief Scientific Officer | – | Oct 24, 2023 | 0 |
| Monohon Ted | Chief Accounting Officer & VP | 27,440 | Mar 6, 2023 | 0 |
| Smith Karen L. | Chief Medical Officer | 194,690 | Feb 2, 2023 | 0 |
| McDowell Caryn Gordon | Chief Legal & Adm. Officer | 122,500 | Jun 8, 2022 | 0 |
| Holsinger Leslie | EVP, Preclinical Development | 148,080 | Jun 8, 2022 | 0 |
| Low Philip S | Director | 63,974Indirect | May 23, 2022 | 0 |
| Sabbagh Marwan | Director | – | Mar 16, 2022 | 0 |
| Lowe Christopher P. | Interim CEO, COO & CFO | 265,000 | Mar 4, 2022 | 0 |
| Detke Michael J. | Chief Medical Officer | 140,000 | Mar 4, 2022 | 0 |
| Lynch Casey | Chief Executive Officer | 109,895 | Jan 5, 2022 | 0 |
| Dominy Stephen S. | Chief Scientific Officer | 1,217,086Indirect | Jan 5, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 29, 2025 (view filing) | Dec 26 | 3 days | Benatti LucaDirector | SSale | −50.0K | $3.47 | −$173.5K | −56.1%39.2K after | |
| Sep 3, 2024 (view filing) | Aug 29-30 | 5 days | Thye DirkCEO AND CHIEF MEDICAL OFFICER | PPurchase | +154.5K | $0.695 | +$107.4K | +22.4%843.9K after | 2 lots |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | Ryan Charles S.PRESIDENT | PPurchase | +48.4K | $0.65 | +$31.5K | +65.3%122.5K after | |
| Aug 21, 2024 (view filing) | Aug 19-21 | 2 days | Hannah BrendanCHIEF BUSINESS OFFICER AND COO | PPurchase | +38.9K | $0.6209 | +$24.2K | +15.1%296.5K after | 6 lots |
| Dec 14, 2023 (view filing) | Dec 12-14 | 2 days | Lamond DavidDirector | PPurchase | +45.6K | $1.02 | +$46.5K | +2.0%2.35M after | 3 lots |
| Dec 14, 2023 (view filing) | Dec 12 | 2 days | Lamond DavidDirector | PPurchase | +22.3K | $1.02 | +$22.8K | +1.0%2.30M after | |
| Dec 7, 2023 (view filing) | Dec 5-7 | 2 days | Lamond DavidDirector | PPurchase | +57.4K | $1.01 | +$58.1K | +2.6%2.28M after | 3 lots |
| Dec 1, 2023 (view filing) | Nov 29-Dec 1 | 2 days | Lamond DavidDirector | PPurchase | +43.1K | $0.94 | +$40.5K | +2.0%2.22M after | 3 lots |
| Aug 31, 2023 (view filing) | Aug 30-31 | 1 day | Lamond DavidDirector | PPurchase | +82.1K | $1.32 | +$107.9K | +3.9%2.18M after | 2 lots |
| Aug 17, 2023 (view filing) | Aug 15-17 | 2 days | Lamond DavidDirector | PPurchase | +250.0K | $1.30 | +$325.7K | +13.5%2.10M after | 3 lots |
| Aug 11, 2023 (view filing) | Aug 10 | 1 day | Thye DirkChief Executive Officer | PPurchase | +88.0K | $1.26 | +$110.9K | +24.4%448.9K after | |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | Thye DirkChief Executive Officer | PPurchase | +80.0K | $1.24 | +$99.2K | +28.5%360.9K after | |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | Hannah BrendanChief Business Officer | PPurchase | +71.8K | $1.22 | +$87.5K | +55.3%201.6K after | |
| Aug 9, 2023 (view filing) | Aug 8 | 1 day | McLoughlin MargaretDirector | PPurchase | +8.00K | $1.23 | +$9.84K | New position8.00K after | |
| Mar 6, 2023 (view filing) | Mar 6 | Same day | Monohon TedChief Accounting Officer & VP | SSale | −1.87K | $0.98 | −$1.83K | −6.4%27.4K after | |
| Jun 8, 2022 (view filing) | Jun 6 | 2 days | McDowell Caryn GordonChief Legal & Adm. Officer | SSale | −10.8K | $2.86 | −$30.9K | −8.1%122.5K after | |
| Nov 12, 2021 (view filing) | Nov 12 | Same day | Dominy Stephen S.Chief Scientific Officer | PPurchase | +763 | $14.40 | +$11.0K | +0.1%1.22M after | |
| Oct 12, 2021 (view filing) | Oct 8 | 4 days | McLoughlin MargaretDirector | SSale | −1.00K | $88.93 | −$88.9K | −100.0%0 after | |
| Oct 7, 2021 (view filing) | Oct 5 | 2 days | Lowe Christopher P.COO & Chief Financial Officer | SSale | −4.96K | $98.50 | −$488.9K | −7.6%60.0K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | McLoughlin MargaretDirector | SSale | −6.00K | $95.44 | −$572.6K | −100.0%0 after | 5 lots |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Lowe Christopher P.COO & Chief Financial Officer | SSale | −22.0K | $95.31 | −$2.10M | −42.3%30.0K after | 5 lots |
| Aug 12, 2021 (view filing) | Aug 10 | 2 days | Detke Michael J.Chief Medical Officer | SSale | −10.0K | $100.00 | −$1.00M | −100.0%0 after | |
| Jul 7, 2021 (view filing) | Jul 6-7 | 1 day | Detke Michael J.Chief Medical Officer | SSale | −58.3K | $54.04 | −$3.15M | −100.0%0 after | 8 lots |